Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo.
- 1 March 1995
- journal article
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 6 (3) , 327-343
- https://doi.org/10.1091/mbc.6.3.327
Abstract
SPARC is a secreted glycoprotein that has been shown to disrupt focal adhesions and to regulate the proliferation of endothelial cells in vitro. Moreover, peptides resulting from the proteolysis of SPARC exhibit angiogenic activity. Here we describe the temporal synthesis, turnover, and angiogenic potential of SPARC in the chicken chorioallantoic membrane. Confocal immunofluorescence microscopy revealed specific expression of SPARC protein in endothelial cells, and significantly higher levels of SPARC were observed in smaller newly formed blood vessels in comparison to larger, developmentally older vessels. SPARC mRNA was detected at the earliest stages of chorioallantoic membrane morphogenesis and reached maximal levels at day 13 of embryonic development. Interestingly, steady-state levels of SPARC mRNA did not correlate directly with protein accumulation; moreover, the protein appeared to undergo limited degradation during days 10-15. Incubation of [125I]-SPARC with chorioallantoic membranes of different developmental ages confirmed that extracellular proteolysis occurred during days 9-15, but not at later stages (e.g., days 17-21). Comparison of peptides produced by incubation with chorioallantoic membranes with those generated by plasmin showed an identical pattern of proteolysis. Plasmin activity was present throughout development, and in situ zymography identified sites of plasminogen activator activity that corresponded to areas exhibiting high levels of SPARC expression. Synthetic peptides from a plasmin-sensitive region of SPARC, between amino acids 113-130, stimulated angiogenesis in the chorioallantoic membrane in a dose-dependent manner; in contrast, intact SPARC was inactive in similar assays. We have shown that SPARC is expressed in endothelial cells of newly formed blood vessels in a manner that is both temporally and spatially restricted. Between days 9 and 15 of chorioallantoic membrane development, the protein undergoes proteolytic cleavage that is mediated, in part, by plasmin. SPARC peptides released specifically by plasmin induce angiogenesis in vivo. We therefore propose that SPARC acts as an intrinsic regulator of angiogenesis in vivo.Keywords
This publication has 58 references indexed in Scilit:
- Complex formation of human thrombospondin with osteonectinEuropean Journal of Biochemistry, 1988
- Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDaAnalytical Biochemistry, 1987
- Radioimmunoassay for osteonectin. Concentrations in bone, nonmineralized tissues, and bloodJournal of Bone and Mineral Research, 1987
- The efficiency of systematic sampling in stereology and its prediction*Journal of Microscopy, 1987
- In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization.The Journal of cell biology, 1987
- Amiloride selectively inhibits the urokinase‐type plasminogen activatorFEBS Letters, 1987
- Forskolin and Phorbol Esters Reduce the Same Potassium Conductance of Mouse Neurons in CultureScience, 1987
- [28] Biological activity of human plasma copper-binding growth factor glycyl-l-histidyl-l-lysinePublished by Elsevier ,1987
- Basic fibroblast growth factor induces angiogenesis in vitro.Proceedings of the National Academy of Sciences, 1986
- Human platelets contain and secrete osteonectin, a major protein of mineralized bone.Proceedings of the National Academy of Sciences, 1986